Evaluating the potential of polyester nanoparticles for per oral delivery of amphotericin B in treating visceral leishmaniasis

Journal of Biomedical Nanotechnology

Volumn 8, Issue 4, 2012, Pages 695-702

  Italia, J L ^a   Ravi Kumar, M N V ^a   Carter, K C ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

Amphotericin B; Leishmania donovani; Nanoparticles

Indexed keywords

ADVERSE SIDE EFFECTS; AMPHOTERICIN B; BONE MARROW; CONTROL VALUES; IN-VITRO; LEISHMANIA; NANOPARTICLE FORMULATION; NEPHROTOXICITY; ORAL DELIVERY; PARASITE-; POLYESTER NANOPARTICLES; SCALE-UP; SIDE EFFECT; VISCERAL LEISHMANIASIS;

DRUG INTERACTIONS; SODIUM;

NANOPARTICLES;

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; NANOPARTICLE; POLYESTER; POLYESTER NANOPARTICLE; STIBOGLUCONATE SODIUM; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTILEISHMANIA ACTIVITY; ANTIPROTOZOAL ACTIVITY; ARTICLE; BONE MARROW; DRUG FORMULATION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LEISHMANIA DONOVANI; MACROPHAGE; MOUSE; NONHUMAN; PARASITE CONTROL; PARASITE LOAD; VISCERAL LEISHMANIASIS;

ADMINISTRATION, ORAL; AMPHOTERICIN B; ANIMALS; ANTIPROTOZOAL AGENTS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MACROPHAGES; MICE; MICE, INBRED BALB C; NANOPARTICLES; POLYESTERS;

EID: 84865136915     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2012.1414     Document Type: Article

References (20)

1. A. Clam, A current perspective on leishmaniasis. J. Glob. Infect. Dis. 2, 124 (2010).
2. WHO, Report of a meeting of the WHO Expert Committee on the Control of Leishmaniases, Geneva, 22-26 March 2010, WHO Technical Report Series 949 WHO Press.
3. J. Aagaard-Hansen, N. Nombela, and J. Alvar, Population movement: A key factor in the epidemiology of neglected tropical diseases. Trop. Med. Int. Health 15, 1281 (2010).
4. D. Claborn, P. Masuoka, M. Morrow, and L. Keep, Habitat analysis of North American sand flies near veterans returning from Leishmania-endemic war zones. Int. J. Health Geogr 18, 7 (2008).
5. A. Pavli and H. C. Maltezou, Leishmaniasis, an emerging infection in travellers. Int. J. Infect. Dis. 14, e1032 (2010).
6. E. M. Moore and D. N. Lockwood, Treatment of visceral leishmaniasis. J. Glob. Infect. Dis. 2, 151 (2010).
7. P. L. Olliaro, Drug combinations for visceral leishmaniasis. Curr. Opin. Infect. Dis. 23, 595 (2010).
8. F. Meheus, M. Balasegaram, P. Olliaro, S. Sundar, S. Rijal, M. A. Faiz, and M. Boelaert, Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent. PLoS Negl Trop Dis. 4, e818 (2010).
9. S. Sundar, J. Chakravarty, D. Agarwal, M. Rai, and H. W. Murray, Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl. J. Med. 362, 504 (2010).
10. G. Delmas, S. Park, Z. W. Chen, F. Tan, R. Kashiwazaki, L. Zarif, and D. S. Perlin, Efficacy of orally delivered cochleates containing amphotericin B in a murine model of aspergillosis. Antimicrob Agents Chemother 46, 2704 (2002).
11. O. Kayser, C. Olbrich, V. Yardley, A. F. Kiderlen, and S. L. Croft, Formulation of amphotericin B as nanosuspension for oral administration. Int. J. Pharm. 254, 73 (2003).
12. E. K. Wasan, K. Bartlett, P. Gershkovich, O. Sivak, B. Banno, Z. Wong, J. Gagnon, B. Gates, C. G. Leon, and K. M. Wasan, Development and characterization of oral lipid-based amphotericin B formulations with enhanced drug solubility, stability and antifungal activity in rats infected with Aspergillus fumigatus or Candida albicans. Int. J. Pharm. 372, 76 (2009).
13. E. K. Wasan, P. Gershkovich, J. Zhao, X. Zhu, K. Werbovetz, R. R. Tidwell, J. G. Clement, S. J. Thornton, and K. M. Wasan, A novel tropically stable oral amphotericin B formulation [ico-010] exhibits efficacy against visceral leishmaniasis in a murine model. PLoS Negl. Trop. Dis. 4, e913 (2010).
14. J. L. Italia, M. M. Yahya, D. Singh, and M. N. V. Ravi Kumar, Biodegradable nanoparticles improve oral bioavailability of Amphotericin B and show reduced nephrotoxicity against intravenous Fungizone®. Pharm Res. 26, 1324 (2009).
15. P. Gershkovich, E. K. Wasan, M. Lin, O. Sivak, C. G. Leon, J. G. Clement, and K. M. Wasan, Pharamacokinteics and biodistribution of amphoptericin B in rats following oral administration in a novel lipid-based formulation. J. Antimicrob. Chemother. 64, 101 (2009).
16. K. C. Carter, A. B. Mullen, S. Sundar, and R. T. Kenney, Efficacies of vesicular and free sodium stibogluconate formulations against clinical isolates of Leishmania donovani. Antimicrob. Agents Chemother. 45, 3555 (2001).
17. K. C. Carter, A. J. Baillie, J. Alexander, and T. F. Dolan, The therapeutic effect of sodium stibogluconate in BALB/c mice infected with Leishmania donovani is organ-dependent. J. Pharm. Pharmacol. 40, 70 (1988).
18. S. D. Goodwin, J. D. Cleary, C. A. Walawander, J. W. Taylor, and T. H. Jnr Grasela, Pretreatment regimens for adverse events related to infusion of amphotericin B. Clin. Infect Dis. 20, 755 (1975).
19. M. Nahar and N. K. Jain, Preparation, characterization and evaluation of targeting potential of amphotericin B-loaded engineered PLGA nanoparticles. Pharm Res. 26, 2588 (2009).
20. S. C. Hock, Y. M. Ying, and C. L. Wah, A review of the current scientific and regulatory status of nanomedicines and the challenges ahead. PDA J. Pharm. Sci. Technol. 65, 177 (2011).